Radnor, PA, February 3, 2011 QR Pharma, Inc., a developer of novel compounds to treat Alzheimer’s disease (AD), announced today that Jeffrey Cummings, MD, Rachelle Doody, MD, PhD, Martin Farlow, MD and Mary Sano, PhD, have been elected to QR’s Medical Advisory Board.
“As QR continues to grow, it is with pleasure that I announce the appointment of four outstanding and distinguished individuals to our newly established Medical Advisory Board,” said Maria Maccecchini, PhD, CEO of QR. Jeff, Rachelle, Marty and Mary are preeminent experts in the field of neurodegeneration, AD and clinical trial design and strategy. Since QR is a clinical stage company, it is imperative that we have expertise in clinical strategy, development and execution. Specifically, our Medical Advisory Board brings a wealth of knowledge, understanding and hands-on experience in the clinical development of disease modifying AD drugs.
Jeffrey Cummings, MD is Professor of Neurotherapeutics and Drug Development in the Neurological Institute, Cleveland Clinic; he is Director of the Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada and Cleveland, Ohio. Dr. Cummings has expertise in neuropsychiatric assessment, outcomes in clinical trials, clinical trial design and analysis and global clinical trials.
Rachelle Doody, MD, PhD is Professor of Neurology, the Effie Marie Cain Chair in Alzheimer’s Disease Research, and the Director of the Alzheimer’s Disease and Memory Disorders Center at Baylor College of Medicine. Dr. Doody has worked on translational studies, trial design, and instrument development for numerous investigational drugs, and has conducted clinical studies for all of the FDA-approved AD treatments as well as several putatively disease-modifying agents currently undergoing clinical testing. She is an authority on global clinical trials for AD.
Martin Farlow, MD is Professor of Neurology and Vice-Chairman of Research in the Department of Neurology at the Indiana University School of Medicine in Indianapolis. He has been involved in research and clinical care of patients with neurodegenerative diseases, such as AD and other dementing conditions. Dr. Farlow has published in both clinical and basic science areas of AD and related dementias with emphasis on investigational drug trials, molecular genetics, and biological markers for AD.
Mary Sano, PhD is Professor of Psychiatry, Mount Sinai School of Medicine, and Director of Research, Bronx VA Hospital. She has been involved in designing and conducting clinical trials in the areas of AD, Parkinson’s Disease and mild cognitive impairment of aging. In 1989 she received the Florence and Herbert Irving Clinical Research Career Award to develop methodologies for the assessment of therapeutic agents in AD.
Posiphen® is in clinical development as an oral treatment for Alzheimer’s disease (AD). It is a small orally active compound with high blood brain barrier permeability, which lowers amyloid precursor protein (APP) levels. QR conducted a trial in patients with mild cognitive impairment (MCI) to confirm Posiphen’s mechanism of action in humans and correlate it with the pharmacokinetics of the compound and its metabolites in CSF and plasma. Posiphen lowers levels of APP and tau by about 40%, approaching the levels found in healthy volunteers.
About QR Pharma, Inc.
Headquartered in Radnor, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment, Alzheimer’s disease (AD), Parkinson’s disease and Down Syndrome. QR currently has two product development programs – Posiphen for early stage AD and BNC for advanced AD. For more information on QR Pharma, please visit www.qrpharma.com.